Abstract
Obesity is currently an exceptionally common problem in humans. The last several years have produced a significant number of breakthroughs in obesity related areas of investigation. Triglycerides are considered the main form of storage of excess calories in fat. A key enzyme in the synthesis of triglycerides is acylCoA: diacylglycerol acyltransferase (DGAT). Recent studies have shown that mice deficient in this enzyme are resistant to diet induced obesity and have increased insulin and leptin sensitivity. These effects suggest that inhibition of DGAT in vivo may be a novel therapeutic target not only for obesity but also for diabetes.
Keywords: dgat, obesity, type 2 diabetes mellitus, acylcoa: diacylglycerol, acyltransferase, free fatty acids
Related Journals
Current Medicinal Chemistry
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Related Books
Herbal Medicine for Autoimmune Diseases
The NLRP3 Inflammasome: An Attentive Arbiter of Inflammatory Response
Natural Immunomodulators: Promising Therapy for Disease Management
Herbal Immunity Boosters Against COVID-19
Mitochondrial DNA and the Immuno-inflammatory Response: New Frontiers to Control Specific Microbial Diseases
Frontiers in Clinical Drug Research – Anti Allergy Agents
Frontiers in Inflammation
2